RARE — Ultragenyx Pharmaceutical Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1515673 ·
Last close
$16.70
Market Cap
$1.70B
52W High
$39.89
52W Low
$12.73
ADV30
3,709,637
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 173,000,000 141,000,000 -110,000,000 -118,000,000 1,187,000,000 150,000,000 1,556,000,000
Jun 2026 214,000,000 180,000,000 -75,000,000 -92,000,000 1,264,000,000 125,000,000 1,548,000,000
Mar 2026 136,000,000 106,000,000 -169,000,000 -185,000,000 1,296,000,000 175,000,000 1,525,000,000
Dec 2025 207,279,000 177,934,000 -113,283,000 -128,556,000 1,532,000,000 421,000,000 1,605,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-436,829,000
Investing CF
$-19,247,000
Financing CF
$487,841,000
CapEx
$-9,938,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-5.19
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-4,927,000,000
Inventory
$59,000,000
Receivables
$166,000,000
ST Investments
$116,000,000
EBIT TTM
$-447,217,000
Pretax Income TTM
$-529,686,000
Interest Exp TTM
$82,469,000
Analysts
20

Yahoo Snapshot (yfinance, live)

Total Revenue
$730,000,000
EBITDA
$-403,000,000
Free Cash Flow
$-179,376,992
Enterprise Value
$2,495,059,456
Total Cash
$266,000,000
Total Debt
$1,186,000,000
Shares Out
101,924,068
Trailing EPS
$-5.17
Book Value
$-3.70
ROE
—
ROA
-23.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 673,000,000 -535,000,000 -575,000,000 1,532,000,000 1,605,000,000 -80,000,000 -466,000,000
Dec 2024 560,000,000 -536,000,000 -569,000,000 1,503,000,000 1,241,000,000 255,000,000 -414,000,000
Dec 2023 434,000,000 -569,000,000 -607,000,000 1,491,013,000 1,215,599,000 275,414,000 -475,000,000
Dec 2022 363,329,000 -648,919,000 -707,421,000 1,545,444,000 1,192,950,000 352,494,000 -380,465,000

TTM Snapshot

Revenues TTM
$717,212,000
NetIncome TTM
$-585,969,000
OpCashFlow TTM
—
Assets (Latest)
$1,264,000,000
Forward EPS
$1.12

Max Pain — expiry 2026-12-18

max pain strike: $15.00 · spot: $17.73 · call oi: 7,213 · put oi: 2,705
Expected Move to 2026-12-18: ±$2.33 (13.11%) — implied range $15.41 – $20.05 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
SUPN Supernus, Inc. $1.69B $29.04 —
BRVE Braveheart Bio, Inc. $1.69B $18.78 —
SDGR Schrodinger, Inc. $1.68B $25.66 —
STOK Stoke Therapeutics, Inc. $1.73B $26.41 —
ZYME Zymeworks Inc. $1.78B $25.84 —

News headlines (Yahoo Finance, 1h cache)

Ultragenyx Pharmaceutical Targets 2027 Profitability After Deep Cuts and Gene Therapy Launches
2026-11-17 08:12 · Yahoo
Ultragenyx to Participate at Investor Conferences in London
2026-11-11 13:30 · Yahoo
Mereo BioPharma Reports Third Quarter 2026 Financial Results
2026-11-09 13:00 · Yahoo
Ultragenyx Announces the Marketing Authorisation Application (MAA) for its Investigational Gene Therapy for MPS IIIA (Sanfilippo syndrome Type A) is Under Review with the UK Medicines and Healthcare P
2026-11-06 08:30 · Yahoo
Ultragenyx Pharmaceutical Inc (RARE) Q3 2026 Earnings Call Highlights: Gene Therapy Launches, ...
2026-11-05 17:03 · Yahoo
Ultragenyx Pharmaceutical (RARE) Stock Looks Fairly Valued After Upcoming FDA Decisions
2026-11-04 16:12 · Yahoo
Ultragenyx (RARE) Q3 2026 Earnings Call Transcript
2026-11-04 15:29 · Yahoo
Ultragenyx Pharmaceutical Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Gene Therapy Launches Could Be A Game Changer For Ultragenyx Stock (RARE)
2026-11-04 13:10 · Yahoo
Ultragenyx Pharmaceutical (RARE) Recasts The Story After FDA Approvals As Valuation Debate Builds
2026-11-04 11:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.